



Press release

May 2, 2019

Gothenburg

Vitrolife has received order for 20 EmbryoScope+ to leading clinic in China

In March, Vitrolife AB (publ) received market approval for the time-lapse incubator EmbryoScope+ in China. The company has now received order for 20 EmbryoScope+ to be installed at a leading clinic in China during the second quarter. The order is the largest single order for EmbryoScope+ so far for Vitrolife.

EmbryoScope+ is a time-lapse system with an integrated incubator with a capacity for fifteen patients. Vitrolife is the market leader of time-lapse systems for use in assisted reproduction for undisturbed culture and improved selection of embryos. In March, Vitrolife received market approval for EmbryoScope+ in China, the world's largest market measured in number of IVF treatments. The received order includes 20 EmbryoScope+ time-lapse incubators that provide a time-lapse capacity of about 15,000 treatments per year, the highest time-lapse capacity in a single clinic in the world. The order is expected to be delivered and accounted for during the second quarter. "We are delighted to receive this prestige order as a result of the market approval during the first quarter," says Thomas Axelsson, CEO of Vitrolife.

May 2, 2019
Gothenburg
VITROLIFE AB (publ)
Thomas Axelsson, CEO

Contact persons:

Thomas Axelsson, CEO, tel: +46 31 721 80 01

Mikael Engblom, CFO, tel: +46 31 721 80 14

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets products for assisted reproduction.

Vitrolife today has approximately 390 employees and the company's products are sold in approximately 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg. Corporate ID number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com

This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 8.30 am CET on May 2, 2019.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.